Live Marvell Technology Vote →

Never Miss Important Company Updates Again

Get AI-powered summaries of SEC filings delivered to your inbox

Follow your favorite stocks and get email alerts when they release important updates. Completely free.

Covers 5,000+ public companies
Get started →
Sign up to stay up to date with the stocks you care about
Follow Design Therapeutics, Inc.

Get SEC filing alerts via email and in your feed for Design Therapeutics, Inc.

DSGN

Design Therapeutics, Inc.

About Design Therapeutics, Inc.

Design Therapeutics Inc. develops small-molecule gene targeted chimeras (GeneTAC®) to treat inherited nucleotide repeat expansion diseases. Its platform modulates gene expression by targeting specific DNA sequences, aiming to restore normal cellular function. Core programs include treatments for Friedreich ataxia, Fuchs endothelial corneal dystrophy, myotonic dystrophy type-1, and Huntington's disease. The company focuses on disease-modifying therapies with broad tissue distribution, leveraging proprietary chemistry for scalable, targeted genomic medicines.
This description was generated via AI from an annual report. Updated 8 months ago.

Latest SEC Filings from Design Therapeutics, Inc.

1
1
Design Therapeutics, Inc. Design Therapeutics Reports $17.6 Million Net Loss in Q1 2026

Via official filing (AI summary) | about 1 month ago | 0 comments

2
1
Design Therapeutics, Inc. Design Therapeutics Reports $69.8 Million Net Loss for 2025, Increases R&D Spending

Via official filing (AI summary) | 3 months ago | 0 comments

3
1
Design Therapeutics, Inc. Design Therapeutics Reports Q3 2025 Financial Results with Increased Net Loss and Operating Expenses

Via official filing (AI summary) | 7 months ago | 0 comments

4
1
Design Therapeutics, Inc. Design Therapeutics Reports $19.1 Million Net Loss in Q2 2025, Increases R&D Spending

Via official filing (AI summary) | 10 months ago | 0 comments

5
1
Design Therapeutics, Inc. Design Therapeutics Reports $17.7 Million Net Loss in Q1 2025, Increased R&D Expenses

Via official filing (AI summary) | about 1 year ago | 0 comments

6
1
Design Therapeutics, Inc. Design Therapeutics Reports $49.6 Million Net Loss for 2024, Decreased Operating Expenses

Via official filing (AI summary) | about 1 year ago | 0 comments

7
1
Design Therapeutics, Inc. Design Therapeutics Reports Q3 2024 Financial Results, Advances GeneTACTM Molecule Development

Via official filing (AI summary) | over 1 year ago | 0 comments